1. Sanofi is Buying Another Blood-Disease Biotech for $4.8 Billion

    Sanofi is Buying Another Blood-Disease Biotech for $4.8 Billion
    • Sanofi is buying Belgian biotech Ablynx for $4.8 billion.
    • Ablynx had recently rejected a rival company, Novo Nordisk, after it bid $3.1 billion on the blood-disease drug developer.
    • It's Sanofi's second deal this month after it picked up Bioverativ in an $11.6 billion deal...
    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. With Ablynx, we continue to advance the strategic transformation of our research and development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders.
  3. Topics Mentioned